Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind study of PF-04171327 in rheumatoid arthritis
2009-013223-37Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fosdagrocorat in rheumatoid arthritis (RA) (4 arms), sponsored by Pfizer. Primary endpoints: DAS28-4 (CRP) at Week 2 for PF-04171327 (high and low dose) versus placebo and DAS28-4 (CRP) at Week 2 for prednisone 5 mg versus placebo. Started Aug 2009; status: completed.
02
Drugs
fosdagrocorat
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-013223-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013223-37.